Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 3/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211707 | 0.87 | PPARA (0.59) | PPARASYKCTSSPPARGATM | |
| SCHEMBL1363391 | 0.87 | PPARA (0.59) | PPARASYKCTSSPPARGATM | |
| SCHEMBL1569316 | 0.87 | PPARA (0.59) | PPARASYKCTSSPPARGATM | |
| SCHEMBL15341687 | 0.87 | SYK (0.62) | PPARASYKCTSSPPARGATM | |
| SCHEMBL1568593 | 0.86 | PPARA (0.61) | PPARASYKCTSSPPARGATM | |
| SCHEMBL15159962 | 0.85 | CTSK (0.59) | SYKCTSSATMMAPTIDO1 | |
| SCHEMBL24386959 | 0.84 | PPARA (0.54) | PPARASYKCTSSPPARGATM | |
| SCHEMBL506649 | 0.84 | IDO1 (0.62) | PPARASYKCTSSPPARGMAPT | |
| SCHEMBL19295602 | 0.83 | SYK (0.73) | PPARASYKCTSSATMMAPT | |
| SCHEMBL1365337 | 0.83 | CTSS (0.60) | PPARASYKCTSSPPARGATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958141-B2 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2005-10-25 | — | — | US | disclosed |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2004-09-30 | — | — | US | disclosed |
| US-6699458-B2 | CELL MEMBRANE PERMEABILITIES GREATER THAN THAT OF SUCROSE | BRACCO INTERNATIONAL B.V. (NL) | 2004-03-02 | — | — | US | disclosed |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | disclosed |
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2002-05-09 | — | — | US | disclosed |
| US-6359120-B1 | REACTING ALKYLENE DIAMINE WITH HALOKETONE TO PROVIDE AN ALKYLENE DIAMINEDIKETONE WHICH IS CONVERTED TO ALKYLENE DIAMINEDIOXIME; OR REACTING ALKYLENE DIAMINE WITH FIRST HALOKETONE AND REACTING WITH SECOND HALOKETONE | BRACCO INTERNATIONAL B.V. (NL) | 2002-03-19 | — | — | US | disclosed |
| US-6184361-B1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2001-02-06 | — | — | US | disclosed |
| US-5808091-A | DIAGNOSTIC IMAGING AGENT | BRACCO INTERNATIONAL B.V. | 1998-09-15 | — | — | US | disclosed |
| US-5688487-A | Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 1997-11-18 | — | — | US | disclosed |
| EP-0544412-B1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INT BV (NL) | 1997-07-23 | — | — | EP | disclosed |
| EP-0544412-A2 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | PPARA 4473/4885SYK 3894/4885CTSS 2457/4885 |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | PPARA 4473/4885SYK 3894/4885CTSS 2457/4885 |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | HIF1A, HIF1AN, SLC2A8 | PPARA 4473/4885SYK 3894/4885CTSS 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.